🇺🇸 FDA

Intelligence · Patent portfolio

Regeneron Ireland Designated Patents

Full USPTO pharma patent portfolio for Regeneron Ireland Designated — grant dates, expiration, and drug cross-links.

Patents
8,292
Expiring ≤24m
426

Quick answer

Regeneron Ireland Designated has 8,292 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 426 expire within 24 months — use filters for patent-cliff planning.

Page 1 of 173

  1. US 12428455

    Dominant negative CEBPB and CEBPD proteins and methods of use for decreasing viability of neoplastic cells

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 12426594

    Cryoprotective compositions and methods for protection of a surgical site during cryosurgery

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 12428416

    ERK inhibitors and uses thereof

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 12427148

    Cancer treatment targeted to tumor adaptive responses to protein synthesis stress

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 12427151

    Compositions and method of treating cancer

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 12427155

    Treatment for tau-related diseases

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 12428463

    Chimeric antigen receptors targeting abnormal glycobiology

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 12428489

    Human PD-L2 antibodies and methods of use therefor

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 12427197

    Methods of producing cobalt nanoparticles and hollow metal nanospheres

    Expires Mon Sep 25 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 12421525

    Conjugates comprising AAVs and CAS9 polypeptides

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 12419958

    Clinical formulations

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 12421517

    Genetic modification of mammalian cells to confer resistance to CSF1R antagonists

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 12421302

    CAR-t cells and autoimmune diseases

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 12422364

    Fluorescence spectral shape analysis for analyte recognition

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 12419811

    Hydrogel drug delivery composition

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 12421316

    Bispecific immunotoxins targeting human CD25+CCR4+ tumors and regulatory T-cells

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 12419942

    Use of the Salmonella spp type III secretion proteins as a protective vaccination

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 12420113

    Methods and apparatus for applying tumor treating fields combined with personalized ultra-fractionated stereotactic adaptive radiotherapy

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 12419866

    Compounds and methods for treating an epileptic disorder

    Expires Mon Sep 18 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 12414907

    Peptide having hair growth promoting activity and use thereof

    Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 12414999

    Compositions and methods relating to macrophages and/or monocytes with adhered particles

    Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 12415863

    Compositions and methods for treating cancer

    Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 12415867

    Anti-DCLK1 antibodies and chimeric antigen receptors, and compositions and methods of use thereof

    Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 12414983

    CD200AR ligands for cancer immunotherapy

    Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 12416008

    Compositions and methods of use for small-molecule regulation of CRISPR-Cas9 activity using RNA aptamers

    Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 12415843

    Antibody-interferon fusion proteins for enhancing adoptive T cell therapies for the treatment of cancer

    Expires Mon Sep 11 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 12410232

    Treatment of a canine CD20 positive disease or condition using a canine CD20-specific chimeric antigen receptor

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 12410231

    Natural killer cell products and methods

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 12409181

    Treatment for aortic aneurysms

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 12409220

    Conjugate polypeptides and vaccines for inducing immune responses

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 12409228

    Hydrogel drug delivery systems for the treatment of pediatric growth plate injuries

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 12410132

    Antiplatelet drugs and uses thereof

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 12410398

    Methods of human retinal progenitor cell isolation and culture

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 12410209

    Modified glucocorticoids

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 12409224

    Compositions and methods for the treatment of VEN/AZA resistant acute myeloid leukemia

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 12410399

    Compositions and methods for treating retinal diseases

    Expires Mon Sep 04 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 12404243

    Inhibitors of the Wnt/beta-catenin pathway

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 12403202

    Dosage of claudin-6 conjugates for cancer treatment

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 12403093

    Methods for production of MSC-derived exosomes

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 12403192

    Nanoemulsion compositions for preventing, suppressing or eliminating allergic and inflammatory disease

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 12404347

    Glucuronoxylomannan (GXM) receptor chimeric antigen receptors and use thereof

    Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 12398375

    Methods for improved poxvirus yields

    Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 12396949

    Technology for improving properties of lipid nanoparticles using lipids in which cis-unsaturated bonds are substituted with a silicon atom

    Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 12396988

    Methods of using muscarinic antagonists in the treatment of depression

    Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 12396994

    Compositions for improving physiological function with age

    Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 12396991

    Biomarkers for the diagnosis and treatment of fibrotic lung disease

    Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 12397058

    Metabolically stable prodrugs

    Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 12398193

    Targeted replacement of endogenous T cell receptors

    Expires Mon Aug 21 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many patents does Regeneron Ireland Designated have?

8,292 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).

When do Regeneron Ireland Designated patents expire?

426 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.

Where does this data come from?

USPTO PatentsView bulk data filtered to pharmaceutical CPC classes (A61K, A61P), cross-linked to NovaPharmaNews company and drug profiles. See our data sources page for methodology.

Data attribution: Data sources · Patent directory

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.